Telix setback in drug approval in US, amid Trump workforce cuts to FDA
Telix Pharmaceuticals says it is disappointed by a surprise US Food and Drug Administration decision to ask for more clinical evidence to support approval for its brain cancer imaging agent, a rare setback for the $9 billion ASX-listed diagnostic giant.
Telix shares fell as much as 10 per cent in early trading on Monday after the FDA said it would not approve the company's diagnostic tool called Pixclara, which identifies gliomas, a deadly form of brain cancer, until the company provided additional evidence about its benefits.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
an hour ago
- AU Financial Review
The year's hottest trade has rocketed this ETF to a 50pc return
As the Albanese government faces mounting pressure from US President Donald Trump to increase Australia's defence budget, local investors have been busy riding this year's hottest trade: war stocks. ASX-listed global defence exchange-traded funds have been among this year's best performing ETFs, boosted by Trump administration's push for its Western allies to shoulder more of the military bill. That has benefited global defence companies which have experienced a wave of new orders and government contracts from nations around the world.
AU Financial Review
2 hours ago
- AU Financial Review
Hanwha says it has the green light to buy all of Austal, if it wants
Hanwha says it has been given approval by foreign investment officials in the United States to buy out the entirety of Austal, the ASX-listed shipbuilder that specialises in defence and has a major facility in Alabama. But Austal, which is backed by the billionaire Forrest family and has long pushed back against Hanwha's interest in acquiring the company, accused the Korean conglomerate of misrepresenting the approvals.
AU Financial Review
2 hours ago
- AU Financial Review
PEP finds a perfect private-equity target in ASX darling-turned-dog
It's funny how life works. Late last month, news broke that Scott Didier, the managing director and talisman of ASX-listed building group Johns Lyng Group, had spent a staggering $140 million to buy one of Australia's most iconic pubs, The Beach Hotel in Byron Bay. Two weeks later, Johns Lyng, in which Didier holds an 18 per cent stake, is in the sights of local private equity giant Pacific Equity Partners, in a deal that could value the business at just over $900 million.
